B
Biohaven
Biotech & Life Sciences · New Haven, United States · Founded 2014 · IPO 2017
Talent graph
Biohaven's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Biohaven has talent and traffic
across markets
Patent intelligence
$76M patent portfolio · 66 active families
Where Biohaven concentrates vs peers
Each axis is a top-10 topic across Biohaven and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Capital deployed
Biohaven's 5 investments and acquisitions.
Every disclosed deal where Biohaven appeared as a backer or acquirer, 2016–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
5 deals across Biohaven's capital deployment.
Where the deals concentrate by sector, stage, and decade.
02 · Portfolio market map
Biohaven's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
What the market is saying about Biohaven
An AI-synthesized read of the highest-engagement posts about Biohaven on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biohaven on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.